TPO and autoimmune thrombocytopenic purpura: Studies of ITP patients who responded to eltrombopag and other TPO-RAs have demonstrated that thrombopoietic therapy can correct the monocyte activation defect in regulatory B cells (Bregs) that are functionally impaired in chronic ITP [22, 23].